Transmembrane channel-like 5 drives hepatocellular carcinoma progression by regulating epithelial-mesenchymal transition

Table 1 Baseline information table for transmembrane channel-like 5 expression, n (%)

Characteristics	Low expression of TMC5 (n = 187)	High expression of TMC5 (n = 187)	P value
Gender			0.036
Female	51 (13.64)	70 (18.72)
Male	136 (36.36)	117 (31.28)
Age			0.499
≤ 60	92 (24.60)	85 (22.73)
> 60	95 (25.40)	101 (27.01)
Stage			0.029
I	99 (26.47)	74 (19.79)
II	40 (10.70)	12.57 (12.57)
III	41 (10.96)	44 (11.76)
IV	0	5 (1.34)
T stage			0.023
T1	101 (27.01)	82 (34)
T2	42 (11.23)	53 (16.3)
T3	39 (10.43)	41 (10.96)
T4	2 (0.53)	11 (2.94)
N stage			1.000
N0	134 (35.83)	120 (32.09)
N1	2 (0.27)	2 (0.27)
M stage			0.120
M0	139 (37.17)	129 (34.49)
M1	0	4 (1.07)

TMC5: Transmembrane channel-like 5.

Table 2 Association of transmembrane channel-like 5 expression and clinical characteristics with prognosis in hepatocellular carcinoma patients by uni- and multivariate COX analysis

Characteristics	Total (n)	Univariate analysis		Multivariate analysis
		HR (95%CI)	P value	HR (95%CI)	P value
Gender	373
Female	121	0.79 (0.56-1.13)	0.200
Male	252
Age	373
≤ 60	177	1.21 (0.85-1.71)	0.295
> 60	196
Stage	349
I	173	1.42 (0.868-2.312)	0.164		0.994
II	86
III	85	2.734 (1.792-4.172)	< 0.001	4.803 (0.641-35.997)	0.127
IV	5	5.597 (1.726-18.148)	0.004		0.999
T stage	370
T1	183	1.431 (0.902-2.268)	0.128		0.994
T2	94
T3	80	2.674 (1.761-4.060)	< 0.001	0.673 (0.091-4.997)	0.699
T4	13	5.386 (2.690-10.784)	< 0.001	1.091 (0.120-9.930)	0.938
N stage	258
N0	254	2.03 (0.50-8.28)	0.324
N1	4
M stage	272
M0	268	4.077 (1.281-12.973)	0.017
M1	4
TMC5	373
Low	187	1.499 (1.059-2.122)	0.023	1.210 (0.772-1.895)	0.406
High	186

TMC5: Transmembrane channel-like 5.